India, Oct. 24 -- * FDA APPROVES REVUMENIB FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH A SUSCEPTIBLE NPM1 MUTATION * FDA : APPROVED REVUMENIB, FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH A SUSCEPTIBLE NPM1 MUTATION IN PATIENTS 1 YEAR AND OLDER Source text: Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Published by HT Digital Content Services with permission from The Sunday Guardian....